Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s12888-014-0298-4
Published Online: 2014-12-02
Published Print: 2014-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Dilla, Tatiana
Möller, Jörgen
O’Donohoe, Paul
Álvarez, María
Sacristán, José A
Happich, Michael
Tockhorn, Antje
License valid from 2014-12-01